Grey Wolf Therapeutics appointed serial entrepreneur Edwin Moses as chair, while Harbour BioMed (HBM Holdings) hired Adam Zong as president. Moses’ background includes leadership roles across UK and European life-science companies and prior experience with acquisitions in the sector, including Amgen-related transactions. HBM’s Zong hire follows his prior role as founding CEO of Hengrui Therapeutics U.S., where he led global expansion activities. Grey Wolf also noted its venture funding progress as it develops antigen modulation therapies across cancer, autoimmune disease, and infectious diseases. The moves reflect how mid-stage biotech firms are reshaping leadership to support pipeline execution and scaling operations, particularly ahead of potential partnering and financing milestones.